Patent ID: 9655974
Date: 2017-05-23
CPC Classifications: A61K,A61P

Claim:
1. A compound comprising an FGF21 polypeptide or an analogue thereof, derivatized with A-B-C-D- covalently attached to the alpha amino-group of the N-terminal amino acid of the FGF21 polypeptide (SEQ ID NO:1) or an analogue thereof, wherein the FGF21 analogue has at least 80% identity to SEQ ID NO:1; and wherein: A- is an element of formula I: wherein n is 12, 14, or 16, and * is the point of attachment to -B-, -B- is an element of formula VIII wherein b is 2, c is 0, * is the point of attachment to -C-, and # is the point of attachment to A-; -C- is an element of formula XI: wherein p is 1, q is 2, * is the point of attachment to -D-, and # is the point of attachment to -B-; -D- is an element of formula XIV: wherein s is 1, * is the point of attachment to the FGF21 polypeptide or an analogue thereof and # is the point of attachment to -C-; or a pharmaceutically acceptable salt thereof.